Iconovo AB (publ)

Stockholm Stock Exchange ICO.ST

Iconovo AB (publ) Current Liabilities for the year ending December 31, 2023: USD 952.16 K

Iconovo AB (publ) Current Liabilities is USD 952.16 K for the year ending December 31, 2023, a -58.92% change year over year. Current liabilities are obligations that are expected to be settled within one year, including accounts payable, short-term debt, and other current liabilities.

Iconovo AB (publ) Current Liabilities for the year ending December 31, 2022 was USD 2.32 M.

Key data

Date	Current Liabilities	Total Non-Current Liabilities	Shareholders' Equity	Long-Term Debt

Stockholm Stock Exchange: ICO.ST

Iconovo AB (publ)

CEO	Mr. Johan Waborg
IPO Date	April 6, 2018
Location	Sweden
Headquarters	Medicon Village
Employees	28
Sector	Healthcare
Industries Pharmaceuticals 3D Printing Biotechnology Clinical Trials Cosmetics Drugstores & Retail Pharmacies Pollution Treatment Vaccines

Description

Iconovo AB (publ) develops and licenses inhalation devices in Sweden. It develops ICOres, a flexible multi-dose dry powder inhaler; ICOcap, a capsule based dry powder inhaler; ICOone, a single-dose disposable dry powder inhaler; and ICOpre, a pre-metered dry powder inhaler, as well as provides customized inhalation solutions. It serves generic companies. The company has an agreement with Immune System Regulation AB for the development of an inhaled covid-19 vaccine in Iconovo's inhaler ICOone; and Respiratorius AB (publ) to develop inhalation product to treat COPD. Iconovo AB (publ) was founded in 2013 and is based in Lund, Sweden.

Key trends

Past 5 years